Rejection of human intestinal allografts: Alone or in combination with the liver

K. Abu-Elmagd, S. Todo, A. Tzakis, H. Furukawa, Bakr Nour, J. Reyes, K. Nakamura, C. Scotti-Foglieni, H. El-Hammadi, Z. Kadry, J. Fung, J. Demetris, T. E. Starzl

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The current results of the present series demonstrate that intestinal allografts are more vulnerable to rejection and continue to be at a significantly higher risk long after transplantation compared with isolated liver allograft recipients. Unexpectedly, a combined liver allograft does not protect small bowel from rejection. The necessarily continuous heavy immunosuppression for these unique recipients is potentially self-defeating. This is clearly demonstrated by their high susceptibility to early and late infectious complications after transplantation as reported in this issue. With the minimal graft-versus-host disease threat in this clinical trial, our revised protocol for future intestinal transplantation is to maximize the passenger leukocyte traffic with supplementary bone marrow from the same intestinal donor in an attempt to augment the development of systemic chimerism and the gradual induction of donor-specific nonreactivity.

Original languageEnglish
Pages (from-to)1430-1431
Number of pages2
JournalTransplantation Proceedings
Volume26
Issue number3
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Allografts
Transplantation
Liver
Chimerism
Graft vs Host Disease
Immunosuppression
Leukocytes
Bone Marrow
Clinical Trials

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Abu-Elmagd, K., Todo, S., Tzakis, A., Furukawa, H., Nour, B., Reyes, J., ... Starzl, T. E. (1994). Rejection of human intestinal allografts: Alone or in combination with the liver. Transplantation Proceedings, 26(3), 1430-1431.

Rejection of human intestinal allografts : Alone or in combination with the liver. / Abu-Elmagd, K.; Todo, S.; Tzakis, A.; Furukawa, H.; Nour, Bakr; Reyes, J.; Nakamura, K.; Scotti-Foglieni, C.; El-Hammadi, H.; Kadry, Z.; Fung, J.; Demetris, J.; Starzl, T. E.

In: Transplantation Proceedings, Vol. 26, No. 3, 1994, p. 1430-1431.

Research output: Contribution to journalArticle

Abu-Elmagd, K, Todo, S, Tzakis, A, Furukawa, H, Nour, B, Reyes, J, Nakamura, K, Scotti-Foglieni, C, El-Hammadi, H, Kadry, Z, Fung, J, Demetris, J & Starzl, TE 1994, 'Rejection of human intestinal allografts: Alone or in combination with the liver', Transplantation Proceedings, vol. 26, no. 3, pp. 1430-1431.
Abu-Elmagd K, Todo S, Tzakis A, Furukawa H, Nour B, Reyes J et al. Rejection of human intestinal allografts: Alone or in combination with the liver. Transplantation Proceedings. 1994;26(3):1430-1431.
Abu-Elmagd, K. ; Todo, S. ; Tzakis, A. ; Furukawa, H. ; Nour, Bakr ; Reyes, J. ; Nakamura, K. ; Scotti-Foglieni, C. ; El-Hammadi, H. ; Kadry, Z. ; Fung, J. ; Demetris, J. ; Starzl, T. E. / Rejection of human intestinal allografts : Alone or in combination with the liver. In: Transplantation Proceedings. 1994 ; Vol. 26, No. 3. pp. 1430-1431.
@article{7c32e327a5b34595ba1493bb0c4d8ba7,
title = "Rejection of human intestinal allografts: Alone or in combination with the liver",
abstract = "The current results of the present series demonstrate that intestinal allografts are more vulnerable to rejection and continue to be at a significantly higher risk long after transplantation compared with isolated liver allograft recipients. Unexpectedly, a combined liver allograft does not protect small bowel from rejection. The necessarily continuous heavy immunosuppression for these unique recipients is potentially self-defeating. This is clearly demonstrated by their high susceptibility to early and late infectious complications after transplantation as reported in this issue. With the minimal graft-versus-host disease threat in this clinical trial, our revised protocol for future intestinal transplantation is to maximize the passenger leukocyte traffic with supplementary bone marrow from the same intestinal donor in an attempt to augment the development of systemic chimerism and the gradual induction of donor-specific nonreactivity.",
author = "K. Abu-Elmagd and S. Todo and A. Tzakis and H. Furukawa and Bakr Nour and J. Reyes and K. Nakamura and C. Scotti-Foglieni and H. El-Hammadi and Z. Kadry and J. Fung and J. Demetris and Starzl, {T. E.}",
year = "1994",
language = "English",
volume = "26",
pages = "1430--1431",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Rejection of human intestinal allografts

T2 - Alone or in combination with the liver

AU - Abu-Elmagd, K.

AU - Todo, S.

AU - Tzakis, A.

AU - Furukawa, H.

AU - Nour, Bakr

AU - Reyes, J.

AU - Nakamura, K.

AU - Scotti-Foglieni, C.

AU - El-Hammadi, H.

AU - Kadry, Z.

AU - Fung, J.

AU - Demetris, J.

AU - Starzl, T. E.

PY - 1994

Y1 - 1994

N2 - The current results of the present series demonstrate that intestinal allografts are more vulnerable to rejection and continue to be at a significantly higher risk long after transplantation compared with isolated liver allograft recipients. Unexpectedly, a combined liver allograft does not protect small bowel from rejection. The necessarily continuous heavy immunosuppression for these unique recipients is potentially self-defeating. This is clearly demonstrated by their high susceptibility to early and late infectious complications after transplantation as reported in this issue. With the minimal graft-versus-host disease threat in this clinical trial, our revised protocol for future intestinal transplantation is to maximize the passenger leukocyte traffic with supplementary bone marrow from the same intestinal donor in an attempt to augment the development of systemic chimerism and the gradual induction of donor-specific nonreactivity.

AB - The current results of the present series demonstrate that intestinal allografts are more vulnerable to rejection and continue to be at a significantly higher risk long after transplantation compared with isolated liver allograft recipients. Unexpectedly, a combined liver allograft does not protect small bowel from rejection. The necessarily continuous heavy immunosuppression for these unique recipients is potentially self-defeating. This is clearly demonstrated by their high susceptibility to early and late infectious complications after transplantation as reported in this issue. With the minimal graft-versus-host disease threat in this clinical trial, our revised protocol for future intestinal transplantation is to maximize the passenger leukocyte traffic with supplementary bone marrow from the same intestinal donor in an attempt to augment the development of systemic chimerism and the gradual induction of donor-specific nonreactivity.

UR - http://www.scopus.com/inward/record.url?scp=0028332268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028332268&partnerID=8YFLogxK

M3 - Article

C2 - 8029970

AN - SCOPUS:0028332268

VL - 26

SP - 1430

EP - 1431

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -